Precision NanoSystems offers ground-breaking transfection technology for primary cells

Vancouver, British Columbia, February 23, 2017 –

Precision NanoSystems is helping scientists to push the boundaries of neuroscience research with a range of efficient and easy-to-use primary cell transfection kits. Combining user-friendly NanoAssemblr™ microfluidics systems with advanced nanoparticle technology, the company has developed the Neuro9™, Astro9™ and iNeuro9™ non-viral gene transfection kits to allow rapid and easy knockdown or expression of genes in primary cells, both in vitro and in vivo.

Precision NanoSystems’ innovative transfection kits are optimized for non-viral delivery of short interfering RNA (siRNA), messenger RNA (mRNA) or plasmid DNA (pDNA) into various neural cell types, such as neurons, astrocytes and iPS-derived neurons. This technology offers transfection efficiencies of up to 95 percent with no observed toxicity by taking advantage of an endogenous pathway to deliver the nucleic acid payload. Combined with the company’s NanoAssemblr microfluidic technology, the kits make it fast and easy to reap the benefits of ground-breaking transfection technology.

Each kit includes all the reagents required to generate nanoparticles using the NanoAssemblr systems, and is available for either in vitro or in vivoapplications. This proven technology ensures rapid, high quality and reproducible results with minimal user training, and has already become widely established in the drug formulation field.

To learn more about Precision NanoSystems’ transfection kits or arrange a demo, visit www.precisionnanosystems.com/transfectionreagents.

 

About Precision NanoSystems

Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases.  PNI’s NanoAssemblr™ Transfection Reagents use nanomedicine technology to deliver genetic materials in primary cells vitro and in vivo, enabling disease researchers to easily study gene function in high-value models of disease. PNI’s proprietary NanoAssemblr™ platform enables the rapid, reproducible, and scalable manufacture of nanoparticle formulations for delivery of nucleic acids, drug molecules, and diagnostic agents to cells and tissues in the body. PNI sells its products to leading pharmaceutical and biotechnology companies, and leading academic institutions in over 20 countries worldwide.